

# New MraY<sub>AA</sub> Inhibitors with an Aminoribosyl Uridine Structure and an Oxadiazole

Hongwei Wan <sup>1</sup>, Raja Ben Othman <sup>1</sup>, Laurent Le Corre <sup>1</sup>, Mélanie Poinsot <sup>1</sup>, Martin Oliver <sup>1</sup>, Ana Amoroso <sup>2</sup>, Bernard Joris <sup>2</sup>, Thierry Touzé <sup>3</sup>, Rodolphe Auger <sup>3</sup>, Sandrine Calvet-Vitale <sup>1</sup>, Michaël Bosco <sup>1,\*</sup> and Christine Gravier-Pelletier <sup>1,\*</sup>

<sup>1</sup> Université Paris Cité, CNRS, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, F-75006 Paris, France

<sup>2</sup> Unité de Physiologie et Génétique Bactériennes, Centre d'Ingénierie des Protéines, Département des Sciences de la Vie, Université de Liège, Sart Tilman, B4000 Liège, Belgium

<sup>3</sup> Institute for Integrative Biology of the Cell (I2BC), CNRS, Université Paris Sud, CEA, F-91405 Orsay, France

\* Correspondence: michael.bosco@u-paris.fr (M.B.); christine.gravier-pelletier@u-paris.fr (C.G.-P.); Tel.: +33-176-534 246 (M.B.); +33-176-534-228 (C.G.-P.)


## ELECTRONIC SUPPLEMENTARY MATERIAL

### Table of contents


|  |    |
|--|----|
| <sup>1</sup> H and <sup>13</sup> C Spectra .....   | 1  |
| Protected Nitrile <b>1</b> .....   | 2  |
| Protected Amidoxime <b>2</b> .....   | 3  |
| 10-phenyldecanoic acid <b>4</b> .....  | 4  |
| 2-(Ethoxycarbonyl)undecanoic acid <b>6</b> .....   | 5  |
| 2-Decyldodecanoic acid <b>9</b> .....  | 6  |
| Protected oxadiazole <b>11a</b> .....  | 7  |
| Protected oxadiazole <b>11b</b> .....  | 8  |
| Protected oxadiazole <b>11c</b> .....  | 9  |
| Protected oxadiazole <b>11d</b> .....  | 10 |
| Protected oxadiazole <b>11e</b> .....  | 11 |
| Protected oxadiazole <b>11f</b> .....  | 12 |
| Protected oxadiazole <b>11g</b> .....  | 13 |
| Protected oxadiazole <b>11h</b> .....  | 14 |
| Protected oxadiazole <b>11i</b> .....  | 15 |
| Oxadiazole <b>12a</b> .....  | 16 |
| Oxadiazole <b>12b</b> .....  | 17 |
| Oxadiazole <b>12c</b> .....  | 18 |
| Oxadiazole <b>12d</b> .....  | 19 |
| Oxadiazole <b>12e</b> .....  | 20 |
| Oxadiazole <b>12f</b> .....  | 21 |
| Oxadiazole <b>12g</b> .....  | 22 |
| Oxadiazole <b>12h</b> .....  | 23 |
| Oxadiazole <b>12i</b> .....  | 24 |
| Oxadiazole <b>12j</b> .....  | 25 |
| Table S1. Antibacterial activity of compounds <b>12a-12i</b> , and reference compounds. .... | 26 |

**Protected Nitrile 1**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**Protected Amidoxime 2**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**10-phenyldecanoic acid 4**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




**2-(Ethoxycarbonyl)undecanoic acid 6**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**2-Decyldodecanoic acid 9**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**Protected oxadiazole 11a**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




## Protected Oxadiazole 11b


<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)



**Protected Oxadiazole 11c**  
<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**Protected Oxadiazole 11d**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**Protected Oxadiazole 11e**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**Protected Oxadiazole 11f**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**Protected Oxadiazole 11g**

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




### Protected Oxadiazole 11h


<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)



**Protected Oxadiazole 11i**  
<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)






**Oxadiazole 12a**

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)




**Oxadiazole 12b**<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)

**Oxadiazole 12c**

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)




**Oxadiazole 12d**

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)




### Oxadiazole 12e

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)




### Oxadiazole 12f

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)




ppm

**Oxadiazole 12g**

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)




### Oxadiazole 12h

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)




**Oxadiazole 12i**

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)




<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)




### Oxadiazole 12j

<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD)



<sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD)



**Table S1.** Antibacterial activity of compounds **12a-12i**, and reference compounds.

| Compounds           | CMI ( $\mu\text{g/mL}$ )             |  |   |  |   |   |
|---------------------|--------------------------------------|--|---|--|---|---|
|                     | Gram -                               |  |   | Gram +   |   |   |
|                     | <i>Escherichia coli</i><br>ATCC 8730 | <i>Citrobacter<br/>freundii</i><br>ATCC 8090 | <i>Pseudomonas<br/>aeruginosa</i><br>ATCC 27853 | <i>Staphylococcus<br/>aureus</i><br>ATCC 25923 | <i>Staphylococcus<br/>aureus MRSA</i><br>ATCC 43300 | <i>Enterococcus<br/>faecium</i><br>ATCC 19434 |
| <b>12a</b>          | >50                                  | >50  | >50   | >50  | >50   | >50   |
| <b>12b</b>          | >50                                  | >50  | >50   | >50  | > 50  | >50   |
| <b>12c*</b>         | >50                                  | >50  | >50   | 50   | 50  | 50  |
| <b>12d*</b>         | >50                                  | >50  | >50   | >50  | >50   | >50   |
| <b>12e</b>          | >50                                  | >50  | >50   | >50  | >50   | >50   |
| <b>12f*</b>         | >50                                  | >50  | >50   | 50   | 50  | 50  |
| <b>12g</b>          | >50                                  | >50  | >50   | >50  | >50   | >50   |
| <b>12h</b>          | >50                                  | >50  | >50   | > 50   | > 50  | > 50  |
| <b>12i*</b>         | >50                                  | >50  | >50   | > 50   | > 50  | > 50  |
| <b>Piperacillin</b> | 4                                    | 4  | 8   | 4  | >128  | 4   |
| <b>Vancomycin</b>   | -                                    | -  | -   | 1  | 1   | 0.5   |

\* Indicates that the molecule is insoluble in 5%DMSO-water (culture media) at the highest final concentration tested